SkyWater Technology, Inc — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that SkyWater Technology, Inc filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 28, 2025 | $442.14M | Mar 11, 2026 |
| FY2025 | Dec 29, 2024 | $342.27M | Mar 11, 2026 |
| FY2024 | Dec 31, 2023 | $286.68M | Mar 14, 2025 |
| FY2024 | Jan 1, 2023 | $212.94M | Mar 14, 2025 |
| FY2023 | Jan 2, 2022 | $162.85M | Mar 15, 2024 |
| FY2022 | Jan 3, 2021 | $140.44M | Mar 15, 2023 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 28, 2025 | $86.93M | Mar 11, 2026 |
| FY2025 | Dec 29, 2024 | $69.63M | Mar 11, 2026 |
| FY2024 | Dec 31, 2023 | $59.29M | Mar 14, 2025 |
| FY2024 | Jan 1, 2023 | $25.97M | Mar 14, 2025 |
| FY2023 | Jan 2, 2022 | ($7.47M) | Mar 15, 2024 |
| FY2022 | Jan 3, 2021 | $22.69M | Mar 15, 2023 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 28, 2025 | $118.91M | Mar 11, 2026 |
| FY2025 | Dec 29, 2024 | ($6.79M) | Mar 11, 2026 |
| FY2024 | Dec 31, 2023 | ($30.76M) | Mar 14, 2025 |
| FY2024 | Jan 1, 2023 | ($39.59M) | Mar 14, 2025 |
| FY2023 | Jan 2, 2022 | ($50.70M) | Mar 15, 2024 |
| FY2022 | Jan 3, 2021 | ($20.62M) | Mar 15, 2023 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 28, 2025 | ($2.58M) | Mar 11, 2026 |
| FY2025 | Dec 29, 2024 | $6.56M | Mar 11, 2026 |
| FY2024 | Dec 31, 2023 | ($14.79M) | Mar 14, 2025 |
| FY2024 | Jan 1, 2023 | ($29.77M) | Mar 14, 2025 |
| FY2023 | Jan 2, 2022 | ($57.10M) | Mar 15, 2024 |
| FY2022 | Jan 3, 2021 | ($8.64M) | Mar 15, 2023 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 28, 2025 | $14.62M | Mar 11, 2026 |
| FY2025 | Dec 29, 2024 | $15.04M | Mar 11, 2026 |
| FY2024 | Dec 31, 2023 | $10.17M | Mar 14, 2025 |
| FY2024 | Jan 1, 2023 | $9.43M | Mar 14, 2025 |
| FY2023 | Jan 2, 2022 | $8.75M | Mar 15, 2024 |
| FY2022 | Jan 3, 2021 | $4.21M | Mar 15, 2023 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 28, 2025 | $74.88M | Mar 11, 2026 |
| FY2025 | Dec 29, 2024 | $48.03M | Mar 11, 2026 |
| FY2024 | Dec 31, 2023 | $63.91M | Mar 14, 2025 |
| FY2024 | Jan 1, 2023 | $46.30M | Mar 14, 2025 |
| FY2023 | Jan 2, 2022 | $43.60M | Mar 15, 2024 |
| FY2022 | Jan 3, 2021 | $25.03M | Mar 15, 2023 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 28, 2025 | ($28.97M) | Mar 11, 2026 |
| FY2025 | Dec 29, 2024 | $18.46M | Mar 11, 2026 |
| FY2024 | Dec 31, 2023 | $10.08M | Mar 14, 2025 |
| FY2024 | Jan 1, 2023 | ($14.30M) | Mar 14, 2025 |
| FY2023 | Jan 2, 2022 | ($55.68M) | Mar 15, 2024 |
| FY2022 | Jan 3, 2021 | $96.20M | Mar 15, 2023 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 28, 2025 | $24.34M | Mar 11, 2026 |
| FY2025 | Dec 29, 2024 | $7.94M | Mar 11, 2026 |
| FY2024 | Dec 31, 2023 | $8.62M | Mar 14, 2025 |
| FY2024 | Jan 1, 2023 | $17.05M | Mar 14, 2025 |
| FY2023 | Jan 2, 2022 | $30.76M | Mar 15, 2024 |
| FY2022 | Jan 3, 2021 | $85.77M | Mar 15, 2023 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 28, 2025 | $733.91M | Mar 11, 2026 |
| FY2025 | Dec 29, 2024 | $311.81M | Mar 11, 2026 |
| FY2024 | Dec 31, 2023 | $316.76M | Mar 14, 2025 |
| FY2023 | Jan 1, 2023 | $305.76M | Mar 15, 2024 |
| FY2022 | Jan 2, 2022 | $263.60M | Mar 15, 2023 |
| FY2021 | Jan 3, 2021 | $263.21M | Mar 10, 2022 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 28, 2025 | $538.10M | Mar 11, 2026 |
| FY2025 | Dec 29, 2024 | $250.29M | Mar 11, 2026 |
| FY2024 | Dec 31, 2023 | $256.06M | Mar 14, 2025 |
| FY2023 | Jan 1, 2023 | $251.79M | Mar 15, 2024 |
| FY2022 | Jan 2, 2022 | $203.67M | Mar 15, 2023 |
| FY2021 | Jan 3, 2021 | $264.79M | Mar 10, 2022 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 28, 2025 | $187.82M | Mar 11, 2026 |
| FY2025 | Dec 29, 2024 | $55.64M | Mar 11, 2026 |
| FY2024 | Dec 31, 2023 | $53.74M | Mar 14, 2025 |
| FY2023 | Jan 1, 2023 | $53.67M | Mar 15, 2024 |
| FY2022 | Jan 2, 2022 | $61.13M | Mar 15, 2023 |
| FY2021 | Jan 3, 2021 | ($16.0K) | Mar 10, 2022 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 28, 2025 | ($15.06M) | Mar 11, 2026 |
| FY2025 | Dec 29, 2024 | ($133.97M) | Mar 11, 2026 |
| FY2024 | Dec 31, 2023 | ($125.20M) | Mar 14, 2025 |
| FY2023 | Jan 1, 2023 | ($94.07M) | Mar 15, 2024 |
| FY2022 | Jan 2, 2022 | ($54.48M) | Mar 15, 2023 |
| FY2021 | Jan 3, 2021 | ($3.78M) | Mar 10, 2022 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 28, 2025 | $23.22M | Mar 11, 2026 |
| FY2025 | Dec 29, 2024 | $18.84M | Mar 11, 2026 |
| FY2024 | Dec 31, 2023 | $18.38M | Mar 14, 2025 |
| FY2023 | Jan 1, 2023 | $30.03M | Mar 15, 2024 |
| FY2022 | Jan 2, 2022 | $12.92M | Mar 15, 2023 |
| FY2021 | Jan 3, 2021 | $7.44M | Mar 10, 2022 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 28, 2025 | $38.88M | Mar 11, 2026 |
| FY2025 | Dec 29, 2024 | $39.78M | Mar 11, 2026 |
| FY2024 | Dec 31, 2023 | $40.07M | Mar 14, 2025 |
| FY2023 | Jan 1, 2023 | $37.04M | Mar 15, 2024 |
| FY2021 | Jan 2, 2022 | $59.45M | Mar 10, 2022 |
| FY2021 | Jan 3, 2021 | $72.60M | Mar 10, 2022 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 28, 2025 | 2 | Mar 11, 2026 |
| FY2025 | Dec 29, 2024 | 0 | Mar 11, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 14, 2025 |
| FY2024 | Jan 1, 2023 | 0 | Mar 14, 2025 |
| FY2023 | Jan 2, 2022 | (1) | Mar 15, 2024 |
| FY2022 | Jan 3, 2021 | (1) | Mar 15, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 28, 2025 | 2 | Mar 11, 2026 |
| FY2025 | Dec 29, 2024 | 0 | Mar 11, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 14, 2025 |
| FY2024 | Jan 1, 2023 | 0 | Mar 14, 2025 |
| FY2023 | Jan 2, 2022 | (1) | Mar 15, 2024 |
| FY2022 | Jan 3, 2021 | (1) | Mar 15, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 28, 2025 | 48.61M | Mar 11, 2026 |
| FY2025 | Dec 29, 2024 | 47.70M | Mar 11, 2026 |
| FY2024 | Dec 31, 2023 | 47.03M | Mar 14, 2025 |
| FY2023 | Jan 1, 2023 | 43.70M | Mar 15, 2024 |
| FY2022 | Jan 2, 2022 | 39.84M | Mar 15, 2023 |
| FY2021 | Jan 3, 2021 | 0 | Mar 10, 2022 |